// App-Quantinova.ai

P380 : A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis

Researchers

Presenter

  • S Danese

Principal Investigators

  • A Hart

  • A Dignass

  • G Fiorino

  • E Louis

  • G D'Haens

  • I Dotan

  • G Rogler

  • K Paridaens

  • L Peyrin-Biroulet

Medical Centers

  • IBD center, Humanitas Clinical and Research Center, Milan, Italy

  • St Mark's Hospital, Harrow, London, UK

  • Department of Medicine I, Agaplesion Markus Hospital, Goethe-University, Frankfurt am Main, Germany

  • CHU Liege, Liege, Belgium

  • Academic Medical Center, Amsterdam, Netherlands

  • Division of Urology, Rabin Medical Center, Petah Tikva, Israel

  • Sackler Faculty Of Medicine, Tel-Aviv University, Tel-Aviv, Israel

  • Division of Hematology, University Hospital Zurich, Zurich, Switzerland

  • Global Medical Affairs Gastroenterology, Ferring Pharmaceuticals Center S.A, Saint-Prex, Switzerland

  • Department of Gastroenterology and Inserm u954, Lorraine University, Nancy, France

Locations

  • Italy

  • United Kingdom

  • Germany

  • Belgium

  • Netherlands

  • Israel

  • Switzerland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Budesonide

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved